Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Gray

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breastLawrence J Solin, Robert Gray, Frederick L Baehner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
JAMA Network Open|March 27, 2024
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple MyelomaJohn Devin Peipert, Fengmin Zhao, Ju-Whei Lee, et al.
BMJ Open Diabetes Research & Care|August 6, 2021
Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screeningJana J Anderson, Paul Welsh, Frederick K Ho, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
Science (New York, N.Y.)|October 23, 2025
Calcifying plankton: From biomineralization to global changePatrizia Ziveri, Gerald Langer, Sonia Chaabane, et al.
Science Immunology|October 24, 2020
Itaconate controls the severity of pulmonary fibrosisPatricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breastLawrence J Solin, Robert Gray, Frederick L Baehner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
JAMA Network Open|March 27, 2024
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple MyelomaJohn Devin Peipert, Fengmin Zhao, Ju-Whei Lee, et al.
BMJ Open Diabetes Research & Care|August 6, 2021
Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screeningJana J Anderson, Paul Welsh, Frederick K Ho, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
Science (New York, N.Y.)|October 23, 2025
Calcifying plankton: From biomineralization to global changePatrizia Ziveri, Gerald Langer, Sonia Chaabane, et al.
Science Immunology|October 24, 2020
Itaconate controls the severity of pulmonary fibrosisPatricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
JCO Precision Oncology|September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple CancersScooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Pageof 15